Published DateClear

Start Date

End Date

Category

• Pipeline4

Organizations

• Bausch + Lomb66
• Eyes On Eyecare51
• Alcon, Inc.46
• American Optometric Association37
• Harrow30
• Glaukos27
• Topcon Healthcare25
• Regeneron24
• Aldeyra Therapeutics20
• Sight Sciences19

Tags

• DME3
• FDA3
• AMD2
• Clinical Trials2
• Retina2
• Wet Amd2
• Cell Therapy1
• Diabetic Retinopathy1
• Inherited Retinal Disease1
• Retinitis Pigmentosa1

• Organizations: Bayer AG✕

Clear all

Pipeline

FDA grants Orphan Drug designation to BlueRock's RP cell therapy

Marks second designation for OpCT-001; includes tax credits for qualified clinical testing and, if approved, 7 years of U.S. market exclusivity.

Pipeline

Regeneron releases 2-year data on aflibercept 8 mg for DME

New findings support 1-year data of interval dosing maintenance; shows similarities to Eylea clinical data.

Pipeline

FDA declines BLA approval for Regeneron's high-dose aflibercept

Agency bases response on an ongoing review of inspection findings at a third-party filler. 

Pipeline

FDA grants aflibercept priority review for retinal diseases

Regeneron and Bayer AG are jointly developing aflibercept 8 mg to treat wet AMD, DME, and diabetic retinopathy.